Search

Your search keyword '"Morelli, F"' showing total 24 results
Start Over Author "Morelli, F" Journal annals of oncology
24 results on '"Morelli, F"'

1. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial

Author

Ghi, M. G., Paccagnella, A., Ferrari, D., Foa, P., Alterio, D., Codecà, C., Nolè, F., Verri, E., Orecchia, R., Morelli, F., Parisi, S., Mastromauro, C., Mione, C. A., Rossetto, C., Polsinelli, M., Koussis, H., Loreggian, L., Bonetti, A., Campostrini, F., Azzarello, G., D’Ambrosio, C., Bertoni, F., Casanova, C., Emiliani, E., Guaraldi, M., Bunkheila, F., Bidoli, P., Niespolo, R. M., Gava, A., Massa, E., Frattegiani, A., Valduga, F., Pieri, G., Cipani, T., Da Corte, D., Chiappa, F., and Rulli, E.

Published
2017
Full Text
View/download PDF

2. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

Author

Bracarda, S., Iacovelli, R., Boni, L., Rizzo, M., Derosa, L., Rossi, M., Galli, L., Procopio, G., Sisani, M., Longo, F., Santoni, M., Morelli, F., Di Lorenzo, G., Altavilla, A., Porta, C., Camerini, A., Escudier, B., Martignetti, Angelo, Ricotta, Riccardo, Gasparro, Donatello, Sabbatini, Roberto, Ceresoli, Giovanni Luca, Mosca, Alessandra, Santini, Daniele, Caserta, Claudia, Cavanna, Luigi, Massari, Francesco, Sava, Teodoro, Boni, Corrado, Verzoni, Elena, Cartenì, Giacomo, and Hamzaj, Alketa

Published
2015
Full Text
View/download PDF

5. 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial

Author

Bachner, M., Loriot, Y., Gross-Goupil, M., Zucali, P. A., Horwich, A., Germa-Lluch, J.-R., Kollmannsberger, C., Stoiber, F., Fléchon, A., Oechsle, K., Gillessen, S., Oldenburg, J., Cohn-Cedermark, G., Daugaard, G., Morelli, F., Sella, A., Harland, S., Kerst, M., Gampe, J., Dittrich, C., Fizazi, K., and De Santis, M.

Published
2012
Full Text
View/download PDF

6. 767P Neutrophil-to-lymphocyte ratio (NLR) and systemic inflammation index (SII) as prognostic factors in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis of the Italian population of the SAUL study

Author

Rebuzzi, S.E., primary, Sternberg, C.N., additional, Banna, G.L., additional, Ermacora, P., additional, Morelli, F., additional, Nolè, F., additional, Marandino, L., additional, Panni, S., additional, Massari, F., additional, Hamzaj, A., additional, Milesi, L., additional, Santini, D., additional, De Tursi, M., additional, Scartozzi, M., additional, Astolfi, C., additional, and Fornarini, G., additional

Published
2020
Full Text
View/download PDF

7. 736P Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial

Author

Procopio, G., primary, Cognetti, F., additional, Miceli, R., additional, Milella, M., additional, Mosca, A., additional, Chiuri, V.E., additional, Bearz, A., additional, Morelli, F., additional, Ortega, C., additional, Atzori, F., additional, Donini, M., additional, Passalacqua, R., additional, Mennitto, A., additional, Sepe, P., additional, Martinetti, A., additional, Montone, R., additional, Apollonio, G., additional, Guadalupi, V., additional, Verzoni, E., additional, and Claps, M., additional

Published
2020
Full Text
View/download PDF

8. First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES study

Author

Masini, C., primary, Ciammella, P., additional, Timon, G., additional, Gnoni, R., additional, De Giorgi, U.F.F., additional, Bellia, S.R., additional, Buti, S., additional, Salaroli, F., additional, Milella, M., additional, Mazzarotto, R., additional, Mucciarini, C., additional, Vitale, M.G., additional, Bruni, A., additional, Procopio, G., additional, Kinspergher, S., additional, Nole, F., additional, Morelli, F., additional, Pappagallo, G., additional, buttigliero, C., additional, and Pinto, C., additional

Published
2019
Full Text
View/download PDF

9. A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck

Author

Bossi, P., primary, Merlano, M.C., additional, Ghi, M.G., additional, Rinaldi, G., additional, Caponigro, F., additional, Morelli, F., additional, Airoldi, M., additional, Farnesi, A., additional, Cassano, A., additional, Ferrari, D., additional, Mirabile, A., additional, Tosoni, A., additional, Galizia, D., additional, Moretti, G., additional, Sponghini, A.P., additional, Calareso, G., additional, Vingiani, A., additional, Perrone, F., additional, Falletta, A., additional, and Licitra, L.F., additional

Published
2019
Full Text
View/download PDF

13. Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy

Author

Procopio, G., primary, Cognetti, F., additional, Miceli, R., additional, Milella, M., additional, Mosca, A., additional, Chiuri, V.E., additional, Bearz, A., additional, Morelli, F., additional, Ortega, C., additional, Atzori, F., additional, Passalacqua, R., additional, Ratta, R., additional, de Braud, F.G.M., additional, Cappelletti, V., additional, and Verzoni, E., additional

Published
2018
Full Text
View/download PDF

14. 1140P - A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck

Author

Bossi, P., Merlano, M.C., Ghi, M.G., Rinaldi, G., Caponigro, F., Morelli, F., Airoldi, M., Farnesi, A., Cassano, A., Ferrari, D., Mirabile, A., Tosoni, A., Galizia, D., Moretti, G., Sponghini, A.P., Calareso, G., Vingiani, A., Perrone, F., Falletta, A., and Licitra, L.F.

Published
2019
Full Text
View/download PDF

15. 961P - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES study

Author

Masini, C., Ciammella, P., Timon, G., Gnoni, R., De Giorgi, U.F.F., Bellia, S.R., Buti, S., Salaroli, F., Milella, M., Mazzarotto, R., Mucciarini, C., Vitale, M.G., Bruni, A., Procopio, G., Kinspergher, S., Nole, F., Morelli, F., Pappagallo, G., buttigliero, C., and Pinto, C.

Published
2019
Full Text
View/download PDF

16. First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study

Author

Bersanelli, M., primary, Maines, F., additional, Facchini, G., additional, Gelsomino, F., additional, Zustovich, F., additional, Santoni, M., additional, Verri, E., additional, De Giorgi, U., additional, Masini, C., additional, Morelli, F., additional, Vitale, M.G., additional, Sava, T., additional, Prati, G., additional, Librici, C., additional, Fraccon, A.P., additional, Fornarini, G., additional, Maruzzo, M., additional, Leonardi, F., additional, Caffo, O., additional, and Buti, S., additional

Published
2016
Full Text
View/download PDF

18. Correction to: Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

Author

Bracarda, S., primary, Iacovelli, R., additional, Boni, L., additional, Rizzo, M., additional, Derosa, L., additional, Rossi, M., additional, Galli, L., additional, Procopio, G., additional, Sisani, M., additional, Longo, F., additional, Santoni, M., additional, Morelli, F., additional, Di Lorenzo, G., additional, Altavilla, A., additional, Porta, C., additional, Camerini, A., additional, and Escudier, B., additional

Published
2016
Full Text
View/download PDF

19. Activity of Sequential New Drugs (Nds) Post-Docetaxel (Doc) Failure, in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts). Update from a Multicenter Italian Experience

Author

Caffo, O., primary, De Giorgi, U., additional, Fratino, L., additional, Facchini, G., additional, Basso, U., additional, Alesini, D., additional, Gasparro, D., additional, Ortega, C., additional, Tucci, M., additional, Verderame, F., additional, Campadelli, E., additional, Re, G. Lo, additional, Sabbatini, R., additional, Donini, M., additional, Procopio, G., additional, Sartori, D., additional, Zucali, P.A., additional, Carrozza, F., additional, D'Angelo, A., additional, and Morelli, F., additional

Published
2014
Full Text
View/download PDF

22. Concomitant Chemoradiotherapy (CT/RT) or CETUXIMAB/RT (CET/RT) with or Without Induction Docetaxel/Cisplatin/5-Fluorouracil (TPF) in Locally Advanced Head and Neck Cancer (LASCCHN). Preliminary Toxicity Results of a Randomized, 2x2 Factorial, Phase II-III Study. (NCT01086826)

Author

Ghi, M.G., primary, Paccagnella, A., additional, Ferrari, D., additional, Rocca, M. Cossu, additional, Verri, E., additional, Morelli, F., additional, Azzarello, G., additional, D'Ambrosio, C., additional, Casanova, C., additional, and Floriani, I.C., additional

Published
2012
Full Text
View/download PDF

23. 790P - Activity of Sequential New Drugs (Nds) Post-Docetaxel (Doc) Failure, in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts). Update from a Multicenter Italian Experience

Author

Caffo, O., De Giorgi, U., Fratino, L., Facchini, G., Basso, U., Alesini, D., Gasparro, D., Ortega, C., Tucci, M., Verderame, F., Campadelli, E., Re, G. Lo, Sabbatini, R., Donini, M., Procopio, G., Sartori, D., Zucali, P.A., Carrozza, F., D'Angelo, A., and Morelli, F.

Published
2014
Full Text
View/download PDF

24. Malignant peritoneal mesothelioma: a multicenter study on 81 cases.

Author

de Pangher Manzini, V., Recchia, L., Cafferata, M., Porta, C., Siena, S., Giannetta, L., Morelli, F., Oniga, F., Bearz, A., Torri, V., and Cinquini, M.

Abstract

Background: Malignant peritoneal mesothelioma (MPM) is a rare disease characterized by a difficult diagnosis, different types of presentation, variable course and poor prognosis. Materials and methods: Eighty-one patients with MPM observed in 14 Italian oncology institutions from 1982 to 2007 have been examined with the aim of delineating the history of MPM. Results: Presentation symptoms were ascites, abdominal pain, asthenia, weight loss, anorexia, abdominal mass, fever, diarrhea and vomiting in various associations. Computed tomography scan and echotomography signs were ascites, abdominal mass and peritoneal thickening. Peritoneal fluid cytology (61 cases) was positive for mesothelioma in 31 and for malignancy, not mesothelioma, in 13. Laparoscopy was carried out in 40 cases and laparotomy in 36. Thrombocytosis was present in 59 cases. Associated tumors diagnosed during the lifetime were colorectal cancer in two cases and cheek carcinoma, thyroid carcinoma, tongue carcinoma, bladder carcinoma and testicular seminoma. Thirty patients were treated with surgery and 45 with chemotherapy. The median survival time from diagnosis is 13 months. Ascites, fever and vomiting were significative variables at presentation; only vomiting holds significance in a multivariate analysis. Conclusions: MPM is a disease with various types of presentation, frequently associated with thrombocytosis, sometimes with other tumors. Survival and diagnosis time can differ in various types of MPM. Prognosis is poor. Key words: asbestos, diagnosis, mesothelioma, peritoneum, prognosis, thrombocytosis [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results